今日药学

2022, v.32(05) 379-382

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

HLA-B~*5801和CYP2C9~*3基因检测及对高尿酸血症患者降尿酸药物应用的合理性分析
HLA-B~*5801 and CYP2C9~*3 Gene Tests on the Application of Antihyperuricemic Drugs in Patients with Hyperuricemia

李洁喜;饶媛;史荣华;
LI Jiexi;RAO Yuan;SHI Ronghua;Department of Pharmacy,Chashan Hospital of Dongguan;Department of Internal Medicine,Chashan Hospital of Dongguan;

摘要(Abstract):

目的 分析HLA-B*5801和CYP2C9*5801和CYP2C9*3基因检测与降尿酸药物应用之间的合理性。方法 通过回顾性研究方法,选取2019年6月~2021年5月在某院行HLA-B*3基因检测与降尿酸药物应用之间的合理性。方法 通过回顾性研究方法,选取2019年6月~2021年5月在某院行HLA-B*5801和CYP2C9*5801和CYP2C9*3基因检测的高尿酸血症患者95例,分析HLA-B*3基因检测的高尿酸血症患者95例,分析HLA-B*5801和CYP2C9*5801和CYP2C9*3基因检测结果与降尿酸药物应用之间的情况,以及药物不良反应的相关性。结果 75例患者行HLA-B*3基因检测结果与降尿酸药物应用之间的情况,以及药物不良反应的相关性。结果 75例患者行HLA-B*5801基因检测的阳性率16.0%;82例患者行CYP2C9*5801基因检测的阳性率16.0%;82例患者行CYP2C9*3基因检测,其中*3基因检测,其中*1/*1/*1、*1、*1/*1/*3、*3、*3/*3/*3基因型分别有78,3,1例。别嘌醇和苯溴马隆用药不合理率分别为5.7%(2/35)和73.7%(42/57)。其次,HLA-B*3基因型分别有78,3,1例。别嘌醇和苯溴马隆用药不合理率分别为5.7%(2/35)和73.7%(42/57)。其次,HLA-B*5801和CYP2C9*5801和CYP2C9*3基因检测不合理率分别为25.3%和2.4%。别嘌醇和苯溴马隆出现的药物不良反应分别为17.1%和19.3%。结论 在基层医院,尚存在降尿酸药物和相关基因检测的不合理性,应予重视并个体化用药,保证降尿酸治疗的有效和安全,以及减少不必要的检测。
OBJECTIVE To analyze the rationality of HLA-B*3基因检测不合理率分别为25.3%和2.4%。别嘌醇和苯溴马隆出现的药物不良反应分别为17.1%和19.3%。结论 在基层医院,尚存在降尿酸药物和相关基因检测的不合理性,应予重视并个体化用药,保证降尿酸治疗的有效和安全,以及减少不必要的检测。
OBJECTIVE To analyze the rationality of HLA-B*5801 and CYP2C9*5801 and CYP2C9*3 gene tests on the application of antihyperuricemic drugs in patients with hyperuricemia.METHODS A retrospective study was conducted to analyze the relevant antihyperuricemic drugs and genotypes of 95 patients with hyperuricemia who received HLA-B*3 gene tests on the application of antihyperuricemic drugs in patients with hyperuricemia.METHODS A retrospective study was conducted to analyze the relevant antihyperuricemic drugs and genotypes of 95 patients with hyperuricemia who received HLA-B*5801 and CYP2C9*5801 and CYP2C9*3 gene tests in Dongguan Chashan Hospital from June 2019 to May 2021,as well as adverse drug reactions.RESULTS The positive rate of HLA-B*3 gene tests in Dongguan Chashan Hospital from June 2019 to May 2021,as well as adverse drug reactions.RESULTS The positive rate of HLA-B*5801 gene detection in 75 patients was 16.0%;78,3 and 1 patients with CYP2C9*5801 gene detection in 75 patients was 16.0%;78,3 and 1 patients with CYP2C9*3 genotypes *3 genotypes *1/*1/*1, *1, *1/*1/*3 and *3 and *3/*3/*3 genotypes were found in 82 patients,respectively.The percentages of antihyperuricemic drugs with irrational rate of allopurinol and benzbromarone were5.7%(2/35) and 73.7%(42/57),respectively-The unreasonable rates of HLA-B*3 genotypes were found in 82 patients,respectively.The percentages of antihyperuricemic drugs with irrational rate of allopurinol and benzbromarone were5.7%(2/35) and 73.7%(42/57),respectively-The unreasonable rates of HLA-B*5801 and CYP2C9*5801 and CYP2C9*3 gene detection were 25.3%and 2.4%,respectively.The adverse drug reactions of allopurinol and benzbromarone were 17.1% and 19.3%,respectively.CONCLUSION In primary hospitals,there are still unreasonable application of antihyperuricemic drugs and related gene tests,which should be taken seriously.And the individual medication guidance should be pay attention to ensure the effectiveness and safety of antihyperuricemic drugs treatment and reduce unnecessary tests.

关键词(KeyWords): 高尿酸血症;基因检测;别嘌醇;苯溴马隆;药物不良反应
hyperuricemia;gene tests;allopurinol;benzbromarone;adverse drug reactions

Abstract:

Keywords:

基金项目(Foundation): 东莞市社会发展科技项目(20211800902902)

作者(Authors): 李洁喜;饶媛;史荣华;
LI Jiexi;RAO Yuan;SHI Ronghua;Department of Pharmacy,Chashan Hospital of Dongguan;Department of Internal Medicine,Chashan Hospital of Dongguan;

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享